

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**FTA Guselkumab for treating moderate to severe plaque  
psoriasis [ID1075]**

**Final appraisal determination**

(when no ACD was issued)

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

Equality issues related to the use of the Dermatology Life Quality Index (DLQI) and the Psoriasis Area and Severity Index (PASI) have been addressed consistent with previously published appraisals. The following recommendations have been included:

- When using the PASI, healthcare professionals should take into account skin colour and how this could affect the PASI score, and make the clinical adjustments they consider appropriate.
- When using the DLQI, healthcare professionals should take into account any physical, psychological, sensory or learning disabilities, or communication difficulties, that could affect the responses to the DLQI and make any adjustments they consider appropriate.

One potential equality issue about the ingredients of guselkumab was raised during the scoping process. No comments were received to suggest that guselkumab is manufactured with ingredients that are unacceptable to groups protected by the equality legislation.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

Not applicable.

7. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes, in sections 1.3, 1.4 and 3.8 of the final appraisal determination.

**Approved by Associate Director (name):** Sheela Upadhyaya

**Date:** 20/03/2018